Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Non-Current Assets (2016 - 2025)

Fortress Biotech has reported Non-Current Assets over the past 13 years, most recently at $61.7 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $61.7 million for Q4 2025, up 14.59% from a year ago — trailing twelve months through Dec 2025 was $225.3 million (up 21.77% YoY), and the annual figure for FY2025 was $61.7 million, up 14.59%.
  • Non-Current Assets for Q4 2025 was $61.7 million at Fortress Biotech, down from $62.9 million in the prior quarter.
  • Over the last five years, Non-Current Assets for FBIO hit a ceiling of $106.6 million in Q3 2021 and a floor of $40.8 million in Q3 2024.
  • Median Non-Current Assets over the past 5 years was $57.5 million (2023), compared with a mean of $60.8 million.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 83.42% in 2021 and later plummeted 38.52% in 2022.
  • Fortress Biotech's Non-Current Assets stood at $50.0 million in 2021, then increased by 27.63% to $63.9 million in 2022, then fell by 20.93% to $50.5 million in 2023, then grew by 6.63% to $53.9 million in 2024, then rose by 14.59% to $61.7 million in 2025.
  • The last three reported values for Non-Current Assets were $61.7 million (Q4 2025), $62.9 million (Q3 2025), and $49.5 million (Q2 2025) per Business Quant data.